About: Clinical significance of anti-IFN-alpha antibody titres during interferon therapy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical significance of anti-IFN-alpha antibody titres during interferon therapy Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 September 1987

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у вересні 1987 (uk) im September 1987 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en setiembre de 1987 (ast) scientific article published on 01 September 1987 (en)
publication date	wds:Q69905224-B22B48D8-66CE-46EB-9EC9-81F266C4E376
publication date	1987-09-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q69905224-D8557299-1CBF-451B-9E37-1D92613E903B
language of work or name	English
cites work	wds:Q69905224-018A4DAE-C813-4E9C-BCAF-CF312D43E667 wds:Q69905224-136C568D-6A64-4DF6-8BCF-B8751AB4AA3E wds:Q69905224-3067449F-D9CB-420A-A55A-CB8208E3CC57 wds:Q69905224-3E593A68-3814-41F5-8AA7-33430B48DB61 wds:Q69905224-5EBDB411-00D1-4962-96C2-17162C1A1E31 wds:Q69905224-AD60A5CB-AC66-4B89-A481-3C44C6C686DE wds:Q69905224-CFB2EB80-6FE8-46A2-B203-EAE9411A624E wds:Q69905224-E75D22DF-4669-4BDC-B66E-0735212BAD40
cites work	Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa-2a by intramuscular injection Treatment of hairy-cell leukaemia with recombinant human alpha 2-interferon Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon Antibodies to human leucocyte interferons in cancer patients A radioimmunologic technique to screen for antibodies to α-2 interferon Low incidence of serum neutralizing factors in patients receiving recombinant alfa-2b interferon (Intron A) Patient with circulating antibodies to alpha-interferon
author name string	wds:Q69905224-047BF954-5F34-49D9-86FE-9079D00397CE wds:Q69905224-1A9F5D28-A971-4E4F-8D8F-7FE929852E0B wds:Q69905224-2B7DA943-A054-495C-9E1E-0B192CA09774 wds:Q69905224-30882526-5B9B-4FBA-B6AA-05E71CCB3815 wds:Q69905224-6FDE53C8-8F01-4F80-9C4D-BB61DDBAFF7B wds:Q69905224-7D076B80-217A-496F-972C-8CED64ED3102
author name string	M Freund H Diedrich H Poliwoda H Deicher P von Wussow B Block
rdfs:label	Clinical significance of anti-IFN-alpha antibody titres during interferon therapy (en) Clinical significance of anti-IFN-alpha antibody titres during interferon therapy (nl)
skos:prefLabel	Clinical significance of anti-IFN-alpha antibody titres during interferon therapy (en) Clinical significance of anti-IFN-alpha antibody titres during interferon therapy (nl)
name	Clinical significance of anti-IFN-alpha antibody titres during interferon therapy (en) Clinical significance of anti-IFN-alpha antibody titres during interferon therapy (nl)
title	wds:Q69905224-A1FCF696-B0A0-4383-8F1F-5DED8AD4B183
title	Clinical significance of anti-IFN-alpha antibody titres during interferon therapy (en)
page(s)	wds:Q69905224-DC1B6658-A2AB-4E9F-A64F-D35B1F5143E4
page(s)	635-636
instance of	wds:Q69905224-CD938D09-0651-4E76-99D7-A5ADEC6142D5
instance of	scholarly article
PubMed ID	wds:Q69905224-4C4906D9-8E99-4D1C-BEFE-42FB2977F9AE
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/2887929
PubMed ID	2887929
published in	wds:Q69905224-A337838A-27ED-4E84-A809-DE9DE7F4C85E
published in	The Lancet
issue	wds:Q69905224-7BB87C89-FBE6-463D-BB4D-695908603753
volume	wds:Q69905224-33FE8ECD-09CD-43EE-BD1E-FD6ED788C461
issue	8559
volume	2
DOI	wds:Q69905224-825B86BF-D9A9-4E22-934D-F22788C13BCD
DOI	http://dx.doi.org/10.1016/S0140-6736(87)93034-0
DOI	10.1016/S0140-6736(87)93034-0
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q69905224
is cites work of	Autoimmune Phenomena in Patients with Malignant Carcinoid Tumors During Interferon-α Treatment Resistance to Recombinant Interferon Alfa-2a in Hairy-Cell Leukemia Associated with Neutralizing Anti-Interferon Antibodies Presence of interferon and anti-interferon in patients with systemic lupus erythematosus Neutralising antibodies in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b. Clinical toxicity of the interferons. Natural human antibodies to gamma interferon interfere with the immunomodulating activity of the lymphokine Naturally occurring anti-interferon-alpha 2a antibodies in patients with acute viral hepatitis Effectiveness of leukocyte interferon-alpha treatment in patients with chronic hepatitis C not responsive to recombinant interferon Hairy cell leukaemia: The role of alpha interferon Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection Raynaud's phenomenon and cryoglobulinaemia associated with the use of recombinant human alpha-interferon Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment Antibodies to lymphoblastoid interferon Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial The role of interferons in the treatment of malignant neoplasms Deterioration of mixed cryoglobulinemia during treatment with interferon-alpha-2a High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome. Highly sensitive enzyme immunoassays for antibodies to human tumor necrosis factor (TNF-α) and lymphotoxin (TNF-β) Incidence and in-vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon alpha-2a combined with acitretin or PUVA High dose interferon treatment in chronic hepatitis C. Treatment of HCV: approach to difficult cases No synergistic activity of epirubicin and interferon-alpha 2b in the treatment of hepatocellular carcinoma Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2 alpha Interferon in myelofibrosis Effects of type I-interferons on human thyroid epithelial cells derived from normal and tumour tissue Hairy cell leukaemia Leucocyte-derived interferon-alpha in patients with antibodies to recombinant IFN-alpha 2b Serum-induced suppression of interferon (IFN) activity. Lack of evidence for the presence of specific autoantibodies to IFN-α in normal human sera Interferon therapy for non-A, non-B chronic hepatitis Low incidence of antibody formation due to long-term interferon-?2c treatment of cancer patients [2 year interferon therapy of metastatic carcinoid tumor]
is cites work of	wds:Q38208932-81F8B35D-5F7F-4D64-B784-213FFE86F00E wds:Q54381914-51B5AB72-3363-489D-B5BB-6F89C4556047 wds:Q67668693-CCEDEB05-77F5-452D-B26E-949BC9107379 wds:Q69373330-8C6328EB-9AEA-4D34-ACD2-ED284EF8B3A2

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 171 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software